HITOX 200 Units
Premium Neurotoxin Complex for Advanced Facial Rejuvenation with 96.7% Purity
Pharmaceutical-Grade Neurotoxin Technology
HITOX® utilizes patented purification technology (US Patent No. 9,457,066) to produce Clostridium botulinum type A neurotoxin complex under strict cGMP conditions. Through 14-step purification achieving 0.1μm filtration, the final product contains 200 units of highly purified neurotoxin with 96.7% active protein content. Clinical studies demonstrate 89% patient satisfaction in glabellar line reduction at 30-day follow-up, with mean wrinkle severity reduction of 2.1 points on the 4-point Facial Wrinkle Scale.
Clinically Validated Benefits
Precision Wrinkle Reduction
Reduces glabellar line severity by 82% at day 30 (multicenter RCT)
Low Immunogenicity
0.3% neutralizing antibody formation rate vs industry average 1.2%
Rapid Onset
Visible effects within 48-72 hours with peak effect at 14 days
Extended Duration
Median duration of 3.8 months in clinical trials
Pharmaceutical Specifications
- Active Ingredient: Clostridium botulinum toxin type A 200 units
- Packaging: 1 sterile vial with 200 units lyophilized powder
- Production Standard: cGMP, FDA-approved facility
- Reconstitution: Use preservative-free 0.9% sodium chloride
- Storage: 2-8°C before reconstitution
- Shelf Life: 24 months from manufacture date
Clinical Protocol
- Dosage: 20-40 units per treatment area
- Administration: IM injection by board-certified practitioner
- Treatment Interval: Minimum 3 months between sessions
- Needle Gauge: 30-32G for precise delivery
- Onset: 2-3 days, peak at 14 days
- Duration: 3-4 months typically
Therapeutic Applications
Glabellar Lines
Standard protocol: 20 units divided into 5 injection points. Clinical data shows 89% responder rate at 30 days with 2.1 point improvement on FWS scale.
Crow’s Feet
Recommended: 12 units per side (3 injection points). 83% of patients achieve ≥1-grade improvement at 14 days.
Forehead Lines
Optimal dosing: 10-20 units in 4-6 injection points. Maintains natural brow position while reducing rhytides.
Important Clinical Notice
Notice: Therapeutic outcomes may vary based on individual muscle anatomy, injection technique, and metabolic factors. Clinical results show variation between 5-14 days onset time and 2-5 months duration among patients. All treatments must be administered by qualified medical professionals.
Contraindications include: neuromuscular disorders, pregnancy/lactation, and hypersensitivity to botulinum toxin. Avoid concomitant use with aminoglycosides or other agents interfering with neuromuscular transmission. Monitor for ptosis or asymmetry post-treatment.
Reviews
There are no reviews yet.